PDF(Pubmed)
Abstract：
Background IL-19 and IL-24 induce proinflammatory cytokine production through the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway. The primary objective of this study was to investigate any changes in IL-19 and IL-24 expression between inflammatory bowel disease (IBD) patients and healthy controls, as well as before and after the initiation of biologics. The secondary objective was to investigate any relation between their expression and disease phenotype and activity. Methods IL-19 and IL-24 expression was measured in intestinal tissue samples from 121 patients with moderate to severe IBD versus healthy controls using immunohistochemistry. Their expression was then measured 12 months after treatment on the patient group treated with biologics. The disease activity was measured before and after treatment using the Harvey Bradshaw Index (HBI) for Crohn\'s disease (CD) patients and the Mayo Score (MS) for ulcerative colitis (UC) patients. Data were analyzed using SPSS (IBM Inc., Armonk, New York). Results IL-19 expression was raised in the IBD group versus healthy controls. In the CD group, the IL-19 expression was related with the disease activity score post-biologic treatment. IL-24 was also highly expressed in patients with active UC and CD and was increased post-treatment. Its expression in UC was statistically related with the MS. Conclusions IL-24 and IL-19 are key factors in IBD-related intestinal inflammation and this is one of the few human studies to suggest that. An immunosuppressive role of IL-24 was demonstrated in the UC group. A future use as biomarkers of disease activity and response to treatment might be feasible.
摘要：
背景IL-19和IL-24通过Janus激酶-信号转导子和转录激活因子（JAK-STAT）途径诱导促炎细胞因子的产生。这项研究的主要目的是调查炎症性肠病（IBD）患者和健康对照之间IL-19和IL-24表达的任何变化，以及生物制剂开始之前和之后。次要目的是研究它们的表达与疾病表型和活性之间的任何关系。方法采用免疫组织化学方法检测121例中重度IBD患者与健康对照组的肠组织中IL-19和IL-24的表达。然后在用生物制剂治疗的患者组治疗后12个月测量它们的表达。使用克罗恩病(CD)患者的HarveyBradshaw指数(HBI)和溃疡性结肠炎(UC)患者的Mayo评分(MS)测量治疗前后的疾病活动。使用SPSS(IBMInc.，Armonk,纽约）。结果与健康对照组相比，IBD组IL-19表达升高。在CD组中，IL-19的表达与生物治疗后的疾病活动评分相关.IL-24在患有活动性UC和CD的患者中也高表达,并且在治疗后增加。其在UC中的表达与MS有统计学关系。结论IL-24和IL-19是IBD相关肠道炎症的关键因素，这是为数不多的人类研究之一。在UC组中证明了IL-24的免疫抑制作用。未来用作疾病活动和治疗反应的生物标志物可能是可行的。
